Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer

Journal of Opioid Management
Neal SlatkinHarry Ahdieh

Abstract

To evaluate the long-term safety, tolerability, and effectiveness of oxymorphone extended release (ER) in patients with cancer-related pain. Post hoc analysis of two-1-year open-label extension studies. Multiple US cancer treatment facilities. Patients with cancer pain who had participated in two short-term crossover comparator trials of oxymorphone ER: one open-label and one double-blind randomized. Patients who had been taking oxymorphone ER continued the dose established in the previous study. Patients who had been taking a comparator opioid were switched to an equianalgesic dose of oxymorphone ER. All patients underwent individualized oxymorphone ER dose titration to optimize effectiveness and tolerability. Current, average, worst, and least pain scores were normalized to a 100-point scale. Patients rated treatment on a five-point global assessment of study medication (Poor = 1 to Excellent = 5). All adverse events (AEs) were recorded. Of the 80 patients who entered the extension trials, 26 completed 52 weeks, 7 discontinued owing to loss of effectiveness, and 20 discontinued owing to AEs, most of which were unrelated to study drug. No significant increase in mean (standard deviation [SDD average pain intensity was observed...Continue Reading

Citations

Dec 4, 2014·Expert Opinion on Pharmacotherapy·Sebastiano Mercadante
May 7, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sebastiano MercadanteVittorio Gebbia
May 20, 2017·Clinical Journal of Oncology Nursing·Jeannine M BrantLinda H Eaton
Mar 10, 2017·Expert Opinion on Pharmacotherapy·Sebastiano Mercadante
Mar 23, 2018·Deutsches Ärzteblatt International·Michael SchusterRita Laufenberg-Feldmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.